Kornimate/medical-research-clean huggingface dataset:
effects of hydration to prevent contrast induced nephropathy in pci for st-elevation myocardial infarction.

Conditions: Contrast Induced Nephropathy

Summary: the aim of the study is to test the efficacy of low versus high volume hydration and two different solutions (sodium chloride versus sodium bicarbonate) in preventing contrast induced nephropathy (cin) in st elevation myocardial infarction (stemi) patients undergoing primary pci.

contrast-induced nephropathy (cin) is associated with increased morbidity and mortality after percutaneous coronary interventions (pci). patients with st elevation myocardial infarction (stemi) are at high risk for cin because of hemodynamic instability of the patient, inability to prevent the phenomenon (hydration) and the possible exposure to high volume of contrast media. recent reports have shown incidence of cin up to 19% in this population and a related increase of in-hospital mortality. merten e coll. (jama 2004) reported that sodium bicarbonate infusion before and after contrast exposure in patients with chronic renal failure and without myocardial infarction (ami) is more effective than sodium chloride in preventing cin. up to date there is no evidence of any effective prophylactic measures in patients with stemi undergoing primary pci. the aim of the study is to test the efficacy of low versus high volume hydration and the efficacy of two different solutions (sodium chloride versus sodium bicarbonate) in preventing cin in stemi patients undergoing primary pci. the infusion of the randomized solution will start just after randomization and after determination of baseline serum creatinine. determination of serum creatinine will be repeated at 24, 48 and 72 hours after randomization. creatinine clearance will be calculated with cockroft-gault formula and mdrd.

Eligibility criteria:
inclusion criteria: * age \> 18 years of years * chest pain lasting at least 30 minutes, non responsive to nitrates, associated to st elevation of at least 0.2 mv on surface ecg in two or more contiguous leads or to new left bundle branch block. * informed consent exclusion criteria: * chronic hemodialytic or peritoneal treatment * coronary anatomy unsuitable for pci * need of emergency coronary artery by-pass grafting * post-anoxic coma * pregnancy

Keywords: contrast induced nephropathy stemi pci
prospective pilot study of robot-assisted nipple sparing mastectomy (rnsm)

Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Ductal Breast Carcinoma In Situ; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prophylactic Mastectomy

Summary: this is a pilot study to determine safety, efficacy, and potential risks of robot assisted nipple sparing mastectomy (rnsm), by utilizing the davinci surgical system.

with the advances of breast reconstruction after mastectomy for the treatment of breast diseases including breast cancer, surgical techniques have evolved to preserve the skin flaps and nipple areolar complex (nac) to give better aesthetic outcome without compromising outcome. mastectomy that preserves the nac is called nipple sparing mastectomy (nsm). nsm can provide major psychosocial benefits for patients but is technically demanding and challenging to perform. total mammary glandular excision in nsm can be technically challenging due to small size of the incision and poor visualization of dissection plane. recent studies demonstrate feasibility and safety of performing minimally invasive robot-assisted nsm (rnsm). the technique of rnsm is still novel. this is a single-arm pilot study for feasibility and safety of rnsm.

Eligibility criteria:
inclusion criteria: * surgical candidates, per standard of care for: * nipple sparing resection and reconstruction or * prophylactic mastectomy for risk reduction mastectomy or * treatment of ductal carcinoma in-situ or clinically node negative ct1-t3 breast cancer * surgical candidates for open nsm, per standard of care, with regards to patient anatomic factors and tumor location * patient has an eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: * pregnant or nursing women * patients with: * inflammatory breast cancer * skin involvement with tumor * pre-operative diagnosis (radiological or pathologic) of nipple-areola complex involvement with tumor * grade 3 ptosis of nipple * smokers with heavy current use of nicotine (defined as \> 20 cigarettes/day) * patients that are high risk for anesthesia, as documented in medical record * patients that do not have the ability to give informed consent * prisoner status at surgical clinic visit * bra cup size greater than c cup * previous thoracic radiation history (for any reason)
family study in schizophrenia

Conditions: Schizophrenia; Family; Genetics

Summary: schizophrenia is a severe mental illness which is considered to have, among other, a genetic etiology. one of the most efficient tools in genetic-psychiatry is the investigation of multiplex families. the current study will identify patients of multiplex families and to map their family connections and the presence of mental illnesses among family members.


Eligibility criteria:
inclusion criteria: 1. schizophrenia 2. multiplex family 3. able to understand and sign the informed concent form. 4. hebrew speaker
antimicrobial efficacy of biogenic gold nano particle from pelargonium graveolens leaves extract mouthwash for children

Conditions: Dental Caries; Gingivitis; Periodontitis

Summary: the study is randomized controlled trial ... the null hypothesis of the present study is that there is no antibacterial efficacy of gold nanoparticles of pelargonium graveolens mouthwash against streptococcus mutans and candida albicans . meanwhile the alternative hypothesis of the present study is that gold nanoparticles of pelargonium graveolens mouthwash have antimicrobial activity against streptococcus mutans and candida albicans .

this is double blind study will be conducted among male patients with mild to moderate gingivitis . those patients aged between (7-14 ) years old who attended the second specialized dental health center in baquba city/ diyala governorate/ iraq. patients will be randomly assigned to one of two study groups the first group is gold nano particle from pelargonium graveolens mouthwash , the second chlorhexidine. by using 15ml of it for one minute two times daily for three weeks. in this study a clinical parameters as ( plaque index, gingival index and calculus index ) were assessed at the base line (before mouthwash use), and then assessed three times at one week interval after the base line assessment through the period of mouthwash use. on the other hand, microbiological aspect were assessed for those patients before and three weeks after the use of gold nano particle from pelargonium graveolens mouthwash and chlorhexidine . after three weeks the mean of plaque, gingival, and culculs indices are significantly reduced after the use of biogenic gold nano particle from pelargonium graveolens leaves extract mouthwash.

Eligibility criteria:
inclusion criteria: * the study sample will include a group if children aged (7-14) years, with mild to moderate crowding, attending the specialist dental center in diyala city. * patients with mild to moderate gingivitis as a base line (for standardization). * healthy child without any oral ulceration or systemic medical condition. * cooperative child. * patient did not take any antibiotics or anti-fungal for at least 4 weeks prior to sampling procedure. * children are healthy without any systemic disease . * from the same geographical area ( diyala governorate ). exclusion criteria: * children outside specified age. * children with systemic disease or on medication. * children on a daily fluoride or other therapeutic regimen were excluded from the study. * children 's parents who are smokers (passive smoking ) to reduce the confounding factors. * no more than one child per family to be allowed into the study. * children who their parents refuse to participate in the study.

Keywords: dental caries gold nanoparticle pelargonium graveolens
mitraclip for the treatment of moderate functional mitral regurgitation: evolve-mr

Conditions: Mitral Regurgitation; Heart Failure; Mitral Valve Regurgitation Due to Cardiomyopathy (Disorder)

Summary: this study evaluates the addition of transcatheter mitral valve repair with the mitraclip device to medical treatment in patients with heart failure and moderate functional mitral regurgitation to determine the impact of left ventricular remodelling and patients' functional capacity.

moderate mitral regurgitation in patients with lv dysfunction is associated with increased risk of death and hospitalizations for heart failure (hf) and leads to progressive remodelling of an already damaged left ventricle. medical therapies and cardiac resynchronization therapy (crt) have demonstrated favourable effects on lv remodelling in heart failure patients. given the benefits and safety of transcatheter mitral valve repair with the mitraclip device in severe mr, it is conceivable that this technology could also be safely used in those with moderate mr to reduce mitral regurgitation, improve symptoms and result in lv remodelling. at present, the optimal treatment strategy for heart failure patients and moderate (2+, 2-3+) mitral regurgitation is uncertain therefore the evolve-mr study proposes to evaluate transcatheter mitral valve repair with the mitraclip in such patients to study the effects on lv remodelling and functional capacity. evolve-mr is a randomized study of mitraclip and medical therapy in symptomatic heart failure patients with moderate (2+, 2-3+) secondary mitral regurgitation. the objective of this study is to determine the impact of both therapies on left ventricular remodelling and functional capacity of the target patient population.

Eligibility criteria:
inclusion criteria: * moderate functional mitral regurgitation (2+, 2-3+) * left ventricular ejection fraction \>20% * lvedv 75-110 ml/m2 * symptomatic heart failure (nyha class ii-iv) exclusion criteria: * left ventricular ejection fraction \< 20% * severe functional mitral regurgitation * recent coronary artery bypass graft surgery (cabg) * untreated significant coronary artery disease * mitral valve area \< 4.0cm2 * severe pulmonary hypertension

Keywords: mitral regurgitation transcatheter mitral valve repair
"critical state" early warning score after chd surgery and rapid response team

Conditions: Congenital Heart Disease

Summary: by establishing a warning scoring tool for the early \&#34;critical state\&#34; after congenital heart disease surgery, the multidisciplinary rapid response team is proactively activated, forming an integrated treatment model of early warning-team decision-making-organ assistance.

all children aged 0-14 years admitted to the picu from 2021-2022 were enrolled continuously, and their baseline data such as gender, age, rachs-1 score, cardiopulmonary bypass time, aortic clamping time, whether there was chromosomal lesions, whether there was preoperative endotracheal intubation/heart failure, changes in oxygenation index, lactate, and vasoactive drug scores were obtained. all variables that may lead to composite malignant events including death in the early postoperative period were included, including death, pulmonary hypertension crisis, malignant arrhythmias (supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, high-degree atrioventricular block) requiring antiarrhythmic drugs or pacemaker treatment, cardiopulmonary resuscitation, ecpr, emergency sternal expansion, severe aki, severe ards, neurological complications (cerebral hemorrhage, cerebral infarction), gastrointestinal complications (gastrointestinal bleeding, intestinal obstruction, intestinal necrosis).the variables were included in the machine learning analysis to establish the model.

Eligibility criteria:
inclusion criteria: * pediatrics admitted to icu exclusion criteria: * surgery without cardiopulmonary bypass * neonatal * using extra-corporeal circulation during surgery * delayed chest closing during surgery

Keywords: congenital heart disease early warning system machine learning retrospective study
calprotectin, a biomarker of covid-19 severity (calpro)

Conditions: Severe/Moderate Coronavirus; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes; Old Age

Summary: the purpose of this study is to provide new insights into the pathophysiology of emergency hematopoiesis detected in severe covid-19 patients. the investigators aim to explore the ability of calprotectin to induce an immunosuppressive myeloid program at the hematopoietic stem and progenitor cell (hspc) level, and to identify the receptor(s) involved in this effect. since patients with a hematological malignancy demonstrate a very high propensity to develop a severe covid-19, the investigators will explore how hspcs collected from patients with a myeloid malignancy respond to calprotectin.

emergency myelopoiesis in response to sars-cov-2 infection produce immunosuppressive myeloid cells with accumulation of immature granulocytes and loss of non-classical monocytes. excessive release of calprotectin, the dimer of s100a8/a9 alarmins, by immature granulocytes and activated monocytes reflects this situation. a role of calprotectin has been previously described in the initiation and progression of chronic hematological malignancies such as myelodysplastic syndromes. to provide a rationale for the targeting of alarmin-driven signaling pathways and limit the pathogenic inflammatory response to sars-cov-2 infection, the role of calprotectin in the production of immunosuppressive cells from the bone marrow hematopoietic stem and progenitors cells needs to be investigated in patients with severe covid-19 in comparison with patients with chronic myeloid malignancies (such as chronic myelomonocytic leukemia and myelodysplastic syndromes) and with age-mached healthy controls. a comprehensive and integrated multiomics approach will be used to decipher the features of immunosuppressive cells and identify therapeutic targets in deregulated pathways.

Eligibility criteria:
inclusion criteria: criteria for all groups: * adults ≥ 18 years * dated and signed inform consent \* * \* : written informed consent of relative (trusted person, close family) in case of emergency procedure, by default emergency inclusion notified in medical file and pursuance consent sought. * affiliation with a social security scheme criteria for control group: * age-matched healthy donors criteria for chronic myeloid malignancies: * a diagnosis of low or high-risk myelodysplastic syndromes according to the who 2016 classification * a diagnosis of dysplastic or proliferative chronic myelomonocytic leukemia according to who 2016 criteria for covid-19 patients: * patients with a recent diagnosis (\<7 days since first symptoms) of moderate or severe covid-19 exclusion criteria: * pregnant women * minor patient or major under protection * patients with covid-19 infection and active cancer or a history of cancer within the last 6 months * patients with covid-19 and severe comorbidities including cardiovascular or respiratory diseases, unbalanced diabetes, obesity (imc \>29) * patient on ame (state medical aid)

Keywords: calprotectin hematopoiesis covid-19
oncodrivers in malignant pleural effusions associated with non-small cell lung cancer: a prospective study.

Conditions: Malignant Pleural Effusion; Non-small Cell Lung Cancer

Summary: oncological treatment of patients with disseminated non-small cell lung cancer (nsclc) is depending on the status of programmed death-ligand 1 (pd-l1), anaplastic lymphoma kinase (alk) and epidermal growth factor receptor (egfr), so called oncodrivers. these can be measured in pleural fluid, but the prevalence is uncertain. in a prospective study, the research team aim to measure pd-l1, alk and egfr in patients with pleural fluid cytology positive for nsclc to report the prevalence. also, the study will investigate if the chance of obtaining oncodriver status is depending on the volume analysed and how the lack of oncodrivers influence the following work-up.

the study is a prospective, non-randomized, cohort study of patients with pleural effusion. participants will be recruited from patients referred to the pleura clinic or admitted at the ward at the department of respiratory medicine, næstved hospital, næstved or at the department of respiratory medicine, zealand university hospital, roskilde, which is the two regional centres for workup of pleural effusions. patients will be referred from either general practice or other hospital departments. pleural fluids with cytology positive for nsclc will be tested for oncodrivers (for squamous cell carcinomas (scc): pd-l1, for adenocarcinomas (ac): pd-l1, alk and egfr). follow-up will be 8 weeks after inclusion.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * pleural effusion known or suspected of association with nsclc (pleural fluid cytology positive for cells from nsclc) * patients must be able to give informed consent exclusion criteria: * full oncodriver status measured in any pleural fluid in current work-up * inability to understand written or spoken danish.
a clinical study of pyrotinib in patients with her2-positive advanced colorectal cancer

Conditions: Colorectal Cancer

Summary: to observe the efficacy and safety of pyrotinib maleate in patients with her2-positive advanced colorectal cancer

this study is an investigator-initiated, open-label, two-cohort phase ii trial, assessing the objective response rate (orr) of pyrotinib monotherapy (cohort 1) or in combination with trastuzumab (cohort 2), in her2-positive advanced colorectal cancer. her2 positivity is centrally established by immunohistochemistry (ihc) and silver in situ hybridization (sish). to be her2 eligible the original tumor, or the biopsied metastasis (whichever is last available), must be ihc 3+ or 2+ in more than 50% of cells, confirmed by sish or fluorescence in situ hybridization (fish) with a her2:cep17 ratio ≥ 2.0. for ihc a positive staining (3+) is defined as an intense membrane staining which can be circumferential, basolateral, or lateral of the tumor cells.

Eligibility criteria:
inclusion criteria: * 1. aged 18-75 years, male or female; * 2. ecog performance status 0-2; * 3. recurrent/metastatic advanced colorectal cancer diagnosed by histology or cytology; * 4. patients who progressed on or were intolerable to standard therapy, or those who refused chemotherapy; * 5. at least one measurable lesion according to recist v1.1; * 6. her2 positivity (including amplification, mutation, and overexpression) detected by clinically recognized methods (including pcr, fish, immunohistochemistry, and ngs), and the data obtained by ngs at the pathology department of hospital or qualified gene testing organization could be accepted; * 7.the functional level of the major organs must meet the following requirements (no blood transfusion within 2 weeks prior to screening, no use of leukocytes- or platelet-raising drugs): 1. blood routine: neutrophils (anc) ≥ 1.5 × 10\^9 / l; platelet count (plt) ≥ 90 × 10\^9 / l; hemoglobin (hb) ≥ 90 g / l; 2. blood biochemistry: total bilirubin (tbil) ≤ upper limit of normal (uln); alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 2 × uln（patients with liver metastases were ≤5 × uln）; 3. cardiac color doppler ultrasound: left ventricular ejection fraction (lvef) ≥ 55%; 4. 12-lead electrocardiogram: the qt interval corrected by the fridericia method (qtcf) \< 470 msec; * 8. sign the informed consent and agree to collect the clinical efficacy and information of the patient. exclusion criteria: * 1. the presence of third interstitial effusion (such as a large amount of pleural fluid and ascites) that cannot be controlled by drainage or other methods makes it impossible to evaluate the clinical treatment effect; * 2. history of substance abuse and cannot be cured or with mental disorders; * 3. pregnant or lactating women; patients with fertility who are unwilling or unable to use effective contraception; * 4. severe concomitant disease, or unsuitable to participate in this study decided by the investigator. * 5. prior use of pyrotinib.

Keywords: her2 advanced colorectal cancer pyrotinib
an evaluation of the tobacco prevention toolkit healthy futures: alternative-to-suspension vaping intervention

Conditions: Tobacco Use Cessation; Addiction

Summary: the healthy futures: alternative-to-suspension curriculum is a free, online curriculum developed to educate students and provide them with resources to quit tobacco/nicotine use. the investigation aims to estimate the extent to which healthy futures: alternative-to-suspension changes high school student's knowledge of, attitudes towards, intentions to use, and actual use of tobacco/nicotine.

youth who use tobacco/nicotine products on school campuses are often detained, suspended, or expelled. healthy futures: alternative-to-suspension is an online curriculum that uses principles of motivational interviewing and cognitive behavioral therapy, incorporating a restorative practice and trauma-informed lens. the goals of the study are three-fold: (1) assess changes in the perspectives of school administrators, educators, counselors, and health staff around the feasibility, acceptability, and usefulness of implementing healthy futures: alternative-to-suspension as an appropriate and effective response to tobacco use on campus (including versus suspension or expulsion); (2) assess high school students' acceptability and perceptions of healthy futures: alternative-to-suspension; and (3) estimate the extent to which healthy futures: alternative-to-suspension changes high school students' knowledge of, attitudes towards, intentions/susceptibility to use, and actual use of tobacco/nicotine products. the stanford reach lab and california school-based health alliance (csha) will partner to evaluate healthy futures: alternative-to-suspension using a school-based randomized waitlist-controlled trial in 20 high schools in california (n = 10 healthy futures: alternative-to-suspension treatment schools and 10 control schools).

Eligibility criteria:
inclusion criteria for schools * agree to be randomized to use the healthy futures: alternative-to-suspension curriculum or to use their current standard of care exclusive of healthy futures: alternative-to-suspension * agree that teachers, counselors, or other school personnel will schedule an online survey prior to and after implementation of healthy futures: alternative-to-suspension or current standard of care with students caught using e-cigarettes or other tobacco products and with students self-reporting use of those products and seeking help to quit * has access to a school nurse/school health officer/school counselor or school psychologist * agree that parental consent, where required, will be sought from students prior to survey administration. * agree that the study is in the wider interest of the public health of adolescents and in their schools interest. inclusion criteria for participants adolescents, aged 14-18, from grades 9-12, who are agreeable to participate in the study and provide assent. exclusion criteria: adolescents, aged 14-18 years, from grades 9-12 who do not speak english.

Keywords: tobacco use tobacco use cessation e-cigarette use suspension